Back to Principal


Latest news

Maxion Therapeutics Highly Commended in ‘Employer of the Year’ Category at Cambridge Independent Science and Technology Awards

Maxion Therapeutics Welcomes Dr Arndt Schottelius as New CEO

Maxion Therapeutics’ Breakthrough Science and Innovation Recognised in PwC UK’s Life Sciences Future50 list

Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors

Maxion Therapeutics Expands Team and Facilities with Move to Unity Campus

Maxion Therapeutics Wins ‘Start-up of the Year’ at 2023 Cambridge Independent Science & Technology Awards

Maxion Therapeutics Awarded £2 million Innovate UK Funding to Develop Ion Channel Antibodies for “Hard-to-Treat" Autoimmune Diseases

Maxion Therapeutics’ $16 million pre-Series A to drive antibody development for previously untreatable ion channel and GPCR-driven diseases

Maxion Therapeutics strengthens its Board with the appointment of Ian Tomlinson (Chairman), Tom Weaver (Non-Executive Director), and Aneesh Karatt Vellatt (Director)